|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial显示文摘 | Tom Waddell Ian Chau David Cunningham David Gonzalez Alicia Frances Clare Okines Andrew Wotherspoon Claire Saffery Gary Middleton Jonathan Wadsley David Ferry Wasat Mansoor Tom Crosby Fareeda Coxon David Smith Justin Waters Timothy Iveson Stephen Falk Sar | 2013 | Lancet Oncology2013，，6： | 10 |
| 2 | Ⅲ期结肠癌患者辅助化疗持续时间的影响研究(IDEA研究合作组):基于6项Ⅲ期随机试验数据的前瞻性汇集分析最终结果显示文摘背景:这项前瞻性汇集分析基于6项Ⅲ期随机试验结果,旨在探讨Ⅲ期结肠癌患者接受3个月与6个月辅助化疗后关于无病生存期的劣效性。汇集分析结果未显示非劣效性。在此,我们报告最终的总体生存结果。方法:在这项前瞻性汇集分析中,我们纳入的Ⅲ期结肠癌患者年满18周岁,东部合作肿瘤小组(Eastern Cooperative Oncology Group,ECOG)评分为0~1分,并于2007年6月20日至2015年12月31日在12个国家/地区入组研究(包括CALGB/SWOG 80702、IDEA France、SCOT、ACHIEVE、TOSCA与HORG试验),接受了任一治疗(改良意向性治疗)。患者在医师的建议下,接受为期3个月或6个月的每2周重复一次的FOLFOX方案化疗(氟尿嘧啶+亚叶酸钙+奥沙利铂)或每3周重复一次的CAPOX方案化疗(卡培他滨+奥沙利铂,存在不同使用剂量与使用方法)。主要观察指标是无病生存情况(复发时间,继发性结直肠原发肿瘤,或全因死亡情况),预定次要观察指标是总生存情况(至全因死亡时间)。设定非劣效性界值为HR=1.11。 | 张荣欣 陈功 ANDRÉ T MEYERHARDT J IVESON T | 2021 | 结直肠肛门外科2021，27，1： | 9 |
| 3 | Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus显示文摘AIM:To assess tumour regression grade(TRG)and lymph node downstaging to help define patients who benefit from neoadjuvant chemotherapy.METHODS:Two hundred and eighteen consecutive patients with adenocarcinoma of the esophagus or gastro-esophageal junction treated with surgery alone or neoadjuvant chemotherapy and surgery between 2005and 2011 at a single institution were reviewed.Triplet neoadjuvant chemotherapy consisting of platinum,fluoropyrimidine and anthracycline was considered for operable patients(World Health Organization performance status≤2)with clinical stage T2-4 N0-1.Response to neoadjuvant chemotherapy(NAC)was assessed using TRG,as described by Mandard et al.In addition lymph node downstaging was also assessed.Lymph node downstaging was defined by cN1 at diagnosis:assessed radiologically(computed tomography,positron emission tomography,endoscopic ultrasonography),then pathologically recorded as N0 after surgery;ypN0 if NAC given prior to surgery,or pN0if surgery alone.Patients were followed up for 5 years post surgery.Recurrence was defined radiologically,with or without pathological confirmation.An association was examined between t TRG and lymph node downstaging with disease free survival(DFS)and a comprehensive range of clinicopathological characteristics.RESULTS:Two hundred and eighteen patients underwent esophageal resection during the study interval with a mean follow up of 3 years(median follow up:2.552,95%CI:2.022-3.081).There was a 1.8%(n=4)inpatient mortality rate.One hundred and thirty-six(62.4%)patients received NAC,with 74.3%(n=101)of patients demonstrating some signs of pathological tumour regression(TRG 1-4)and 5.9%(n=8)having a complete pathological response.Forty four point one percent(n=60)had downstaging of their nodal disease(cN1 to ypN0),compared to only 15.9%(n=13)that underwent surgery alone(pre-operatively overstaged:cN1 to pN0),(P<0.0001).Response to NAC was associated with significantly increased DFS(mean DFS;TRG 1-2:5.1years,95%CI:4.6-5.6 vs TRG 3-5:2.8 years,95%CI:2.2-3.3,P<0.0001).Nodal down-staging conferred a significant DFS advantage for those patients with a poor primary tumour response to NAC(median DFS;TRG 3-5 and nodal down-staging:5.533 years,95%CI:3.558-7.531 vs TRG 3-5 and no nodal down-staging:1.114 years,95%CI:0.961-1.267,P<0.0001).CONCLUSION:Response to NAC in the primary tumour and in the lymph nodes are both independently associated with improved DFS. | Fergus Noble Luke Nolan Adrian C Bateman James P Byrne Jamie J Kelly Ian S Bailey Donna M Sharland Charlotte N Rees Timothy J Iveson Tim J Underwood Andrew R Bateman | 2013 | World Journal of Gastroenterology2013，19，48： | 4 |
| 4 | Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial显示文摘 | JY Douillard D Cunningham AD Roth M Navarro RD James P Karasek P Jandik T Iveson J Carmichael M Alakl G Gruia L Awad P Rougier | 2000 | The Lancet2000，，9209： | 4 |
| 5 | Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study显示文摘 | Timothy Iveson Ross C Donehower Irina Davidenko Sergey Tjulandin Andrzej Deptala Mark Harrison Somanath Nirni Kuntegowdanahalli Lakshmaiah Anne Thomas Yizhou Jiang Min Zhu Rui Tang Abraham Anderson Sarita Dubey Kelly S Oliner Elwyn Loh | 2014 | Lancet Oncology2014，，9： | 3 |
| 6 | Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial显示文摘 | John Primrose Stephen Falk Meg Finch-Jones Juan Valle Derek O’Reilly Ajith Siriwardena Joanne Hornbuckle Mark Peterson Myrddin Rees Tim Iveson Tamas Hickish Rachel Butler Louise Stanton Elizabeth Dixon Louisa Little Megan Bowers Sian Pugh O James Garden D | 2014 | Lancet Oncology2014，，6： | 2 |
| 7 | Branded cities:outdoor advertising,urban govern-ance,and the outdoor media landscape 显示文摘 | Kurt Iveson | 2012 | Antipode2012，，1： | 1 |
| 8 | Nucleation, growth andbreakage phenomena in agitated wet granulation processes: a re-view显示文摘 | Iveson S M Lister J D Hapgood K | 2001 | Powder Technology2001，117，2： | 1 |
| 9 | Comparison of Extraction Behaviour and Basicity of some Substituted Malonamides显示文摘 | Spjuth L Liljenzin J O Hudson M I Drew M G B Iveson P B Madic C | 2000 | Solvent Extr Ion Exch2000，18，1： | 1 |
| 10 | Management of advanced colorectal cancer : state of the art 显示文摘 | Saunders M Iveson T | 2006 | Br J Cancer2006，95，2： | 1 |
| 11 | Direct evidence for the cathodic depolarization theory of bacterial corrosion 显示文摘 | Iveson W P | 1996 | Science1996，151，： | 1 |
| 12 | Coalescence of deformable granules in wet granulation processes显示文摘 | L X LIU J D LITSTER S M IVESON | 2000 | AIChE J2000，46，： | 1 |
| 13 | Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer显示文摘 | Clarke-Pearson DL Van Le L Iveson T | 2001 | J Clin Oncol2001，19，19： | 1 |
| 14 | Liquid-bound granule impact deformation and coefficient of restitution显示文摘 | S M IVESON J D LISTER | 1998 | Powder Technology1998，99，： | 1 |
| 15 | Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in post- menopausal patients with advanced breast cancer显示文摘 | Iveson TJ Smith IE Ahem J | 1993 | Cancer Res1993，53，2： | 1 |
| 16 | Nucleation,growth and breakage phenomena in agitated wet granulation process:a review显示文摘 | S M IVESON J D LISTER K HAPGOOD | 2001 | Powder Technology2001，117，： | 1 |
| 17 | The dynamic strength of partially saturated powder compacts:the effect of liquid properties显示文摘 | S M IVESON J A BEATHE N W PAGE | 2002 | Powder Technology2002，127，： | 1 |
| 18 | Advancing Contact Angle of Iron Ores As a Function of Their Hematite and Goethite Content:Implications for Pelletising and Sintering显示文摘 | Iveson S M Holt S Biqqs S | 1992 | Metals and Materials1992，30，10： | 1 |
| 19 | Solution -focused brief therapy显示文摘 | Iveson C | 2002 | Advances in Psychiat- ric Treatment2002，8，2： | 1 |
| 20 | Nucleation, growth and breakage phenomena in agitated wet granulation process:a review 显示文摘 | Iveson MI Litster JD Hapgood K | 2001 | Powder Techno12001，117，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员